Six of eight recently appointed committee members operate clinics that offer peptide therapies. Dr. Haleem Mohammed, who voted yes and argued for harm reduction, serves as Chief Medical Officer of Gameday Men's Health, a clinic network that sells peptide treatments. The FDA itself raised conflict of interest concerns ahead of the meeting. Multiple outlets (STAT News, Healio, BioPharma Dive) documented financial ties between yes voters and the peptide industry.

Advisory committees are supposed to provide independent scientific counsel. When three quarters of the recently appointed members have revenue tied to the products under review, the word "independent" is doing a lot of heavy lifting. This doesn't automatically invalidate their reasoning. But it explains the 8 to 6 split better than the data does.

BPC-157 is the most studied of the group. Its evidence base consists of animal models (primarily rodent gastric ulcer and tendon repair studies) and a small number of early phase human trials. One randomized trial suggested BPC-157 performed no better than placebo, with signals of potential liver toxicity. TB-500 has no completed human efficacy trial demonstrating muscle repair in healthy individuals. KPV has preclinical wound healing data but lacks Phase 2 or 3 trials. MOTS-c has promising mitochondrial biology but only pilot human data. Semax was developed in Russia for cognitive disorders; the evidence is small Russian studies without Western replication. Epitalon's human data on insomnia is negligible.

None of these compounds meet Phase 3 randomized controlled trial standards. FDA career scientists unanimously recommended against all seven peptides. Dr. Adriane Fugh-Berman put it plainly: "Just because a market is large doesn't mean that a product should be legalized. It means that a product should be studied." An opposing committee member, Dr. Brian Lee of USC, said he could not "in good conscience, vote yes."

This is the strongest case the yes voters made. People are already injecting these peptides. They buy them from overseas suppliers labeled "research use only," with unknown purity, unknown dosing, and zero medical oversight. Moving supply into licensed pharmacies with physician prescriptions and USP compounding standards would at least ensure quality control and professional supervision. Dr. Mohammed framed it in physician terms: "When I look at something like saying no to this and pushing it to the gray market, am I doing greater harm?"

Harm reduction is a pragmatic argument, not a scientific one. It assumes the peptides are safe enough that a clean supply is the main barrier to safe use. That's unproven. It also assumes compounding pharmacies will maintain consistent quality (batch to batch inconsistencies were flagged by FDA scientists). And it sets a precedent: popularity and black market availability become de facto arguments for regulatory accommodation, regardless of evidence. Elizabeth Rebello, a dissenting member, warned the panel was "responding to a market-induced demand rather than a decision based in solid science."

Multiple outlets framed this as a win for Robert F. Kennedy Jr.'s "MAHA" (Make America Healthy Again) agenda. Kennedy has publicly advocated for peptide reclassification and told Joe Rogan he's a "big fan" of peptides personally. The recently reconstituted committee composition, with its preponderance of peptide clinic operators, reflects a broader shift in how advisory panels are staffed under the current administration.

The Partnership for Safe Medicines warned this would convert "the American public into involuntary clinical trial participants while severely undermining the economic and safety integrity of the established FDA drug approval system." That's advocacy language. But the concern is real. If compounds with only preclinical data can reach patients through the compounding pathway, it creates a parallel track that bypasses the approval process the FDA exists to enforce. The recommendation is non-binding, and the FDA rarely overrules its advisory committees, though it can.